10 completed, 3 terminated, 2 withdrawn, 1 active not recruiting. 13 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 3.
By phase and status
Follow BI 754091: new trials by email Literature Review of BI 754091 trials Research Report on BI 754091
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) Phase 3 Withdrawn Boehringer Ingelheim 2024-06-27 2024-07-17 A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 BI 765049, Ezabenlimab - Gastrointestinal Cancer, Lung Cancer Phase 1 Terminated Boehringer Ingelheim 21 2024-02-16 2026-10-14 A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) BI 1703880, Ezabenlimab - Solid Tumors Phase 1 Recruiting Boehringer Ingelheim 66 2023-02-24 2026-10-13 A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer BI 765063, Ezabenlimab, BI 836880 - Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 1 Completed Boehringer Ingelheim 48 2022-04-12 2026-09-16 A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors) BI 765063, BI 754091 - Solid Tumors Phase 1 Completed Boehringer Ingelheim 18 2020-12-15 2022-05-10 A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer BI 754091, BI 836880 - Anal Canal Squamous Cell Carcinoma Phase 2 Withdrawn Boehringer Ingelheim 2020-09-14 2021-11-15 A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) BI 1387446 50 μg, BI 754091, BI 1387446 100 μg - Neoplasms Phase 1 Completed Boehringer Ingelheim 42 2020-08-03 2025-08-19 Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer ATP128, BI 754091, VSV-GP128 - Colorectal Cancer, MSS Phase 1 Active not recruiting Amal Therapeutics 96 2019-07-22 2025-01-29 A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) BI 907828, ezabenlimab, BI 754111 - Neoplasms Phase 1 Completed Boehringer Ingelheim 119 2019-06-20 2026-02-18 A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer BI 836880, BI 754091 - Neoplasms Phase 1 Completed Boehringer Ingelheim 21 2019-06-12 2025-10-06 A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours BI 765063, BI 754091 - Solid Tumor, Adult Phase 1 Completed OSE Immunotherapeutics 100 2019-04-16 2025-06-26 Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors Phase 2 Completed Boehringer Ingelheim 211 2019-03-19 2026-01-27 This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 BI 754111, [89Zr]Zr-BI 754111, BI 754091 - Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms Phase 1 Terminated Boehringer Ingelheim 8 2019-01-22 2026-01-13 A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours BI 836880, Ezabenlimab - Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms Phase 1 Completed Boehringer Ingelheim 252 2018-07-05 2025-11-10 This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer Ezabenlimab, BI 754111 - Neoplasms Early Phase 1 Completed Boehringer Ingelheim 146 2018-02-23 2025-12-19 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread BI 891065, BI 754091 - Neoplasms, Neoplasm Metastasis Phase 1 Terminated Boehringer Ingelheim 62 2017-09-08 2024-11-19 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours BI 754091 - Neoplasms Phase 1 Completed Boehringer Ingelheim 110 2016-11-21 2026-01-27
Conditions studied Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Colonic Neoplasms (1) · Dermatofibrosarcoma (1) · Gastrointestinal Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Sponsors Boehringer Ingelheim (15) · Amal Therapeutics (1) · OSE Immunotherapeutics (1)
Countries United States (9) · Japan (7) · United Kingdom (7) · Spain (5) · France (4) · South Korea (4) · Belgium (3) · Germany (3) · Taiwan (3) · Australia (2) · Canada (2) · Netherlands (2) · Poland (2) · Hong Kong (1) · Hungary (1)
Top investigators Scott Kopetz (1)
Results publications PMID 35756842 , PMID 36859619 , PMID 37140602 , PMID 38314087 , PMID 39817655 , PMID 41408891
NIH funding 2017 (4), 2019 (4), 2018 (2)